Vault-13

Patient Square Capital LP

MENLO PARK, CA · CIK 1819257 · 13F filing filed 2026-08-12

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

As an employer

US visa salary filings

Job titleFilingsMedianRange
Deal Professional AssociateMenlo Park, CA 1 $212,500
Private Equity AssociateMenlo Park, CA 1 $165,000

Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: Patient Square Capital LP.

$645.5m reported value +14.5% vs Q1 2026
23positions
80.1%in top 10
6 new 9 added 8 reduced 12 sold out vs Q1 2026

Holdings, Q2 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 ROIVANT SCIENCES LTD SHS ROIV ROIV 8,020,928 $283.9m43.97% 43.97% ReducedShares held: Q3 2025 12.5m, Q4 2025 8.2m, Q1 2026 8.2m, Q2 2026 8.0m -145.1k -145,119 -1.8%
2 REVOLUTION MEDICINES INC COM RVMD RVMD 276,000 $51.7m8.01% 8.01% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 276.0k
3 MIRUM PHARMACEUTICALS INC COM MIRM MIRM 260,500 $30.5m4.72% 4.72% AddedShares held: Q3 2025 104.3k, Q4 2025 298.7k, Q1 2026 230.0k, Q2 2026 260.5k +30.5k +30,500 13.3%
4 ABIVAX SA SPONSORED ADS ABVX ABVX 206,500 $27.5m4.26% 4.26% AddedShares held: Q3 2025 151.8k, Q4 2025 130.0k, Q1 2026 121.2k, Q2 2026 206.5k +85.3k +85,255 70.3%
5 BEIGENE LTD SPONSORED ADR ONC ONC 90,020 $25.7m3.97% 3.97% AddedShares held: Q3 2025 0, Q4 2025 69.3k, Q1 2026 80.5k, Q2 2026 90.0k +9.5k +9,478 11.8%
6 PHARVARIS N V COM PHVS PHVS 671,209 $23.2m3.60% 3.60% AddedShares held: Q3 2025 345.4k, Q4 2025 542.7k, Q1 2026 493.0k, Q2 2026 671.2k +178.2k +178,209 36.1%
7 ARGENX SE SPONSORED ADR ARGX ARGX 23,000 $21.3m3.31% 3.31% ReducedShares held: Q3 2025 15.5k, Q4 2025 26.0k, Q1 2026 36.7k, Q2 2026 23.0k -13.7k -13,718 -37.4%
8 UNITED THERAPEUTICS CORP DEL COM UTHR UTHR 37,120 $20.1m3.12% 3.12% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 37.1k
9 BELITE BIO INC SPONSORED ADS BLTE BLTE 110,000 $16.9m2.62% 2.62% ReducedShares held: Q3 2025 0, Q4 2025 0, Q1 2026 116.7k, Q2 2026 110.0k -6.7k -6,684 -5.7%
10 COGENT BIOSCIENCES INC COM COGT COGT 425,000 $16.4m2.55% 2.55% ReducedShares held: Q3 2025 0, Q4 2025 317.4k, Q1 2026 596.0k, Q2 2026 425.0k -171.0k -171,000 -28.7%
11 DBV TECHNOLOGIES S A SPONSORED ADS DBVT DBVT 909,474 $14.9m2.31% 2.31% AddedShares held: Q3 2025 0, Q4 2025 359.1k, Q1 2026 693.5k, Q2 2026 909.5k +215.9k +215,940 31.1%
12 XENON PHARMACEUTICALS INC COM XENE XENE 220,000 $13.3m2.06% 2.06% ReducedShares held: Q3 2025 0, Q4 2025 136.5k, Q1 2026 227.0k, Q2 2026 220.0k -7.0k -7,000 -3.1%
13 BIONTECH SE SPONSORED ADS BNTX BNTX 134,429 $12.5m1.94% 1.94% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 134.4k
14 ARCUS BIOSCIENCES INC COM RCUS RCUS 355,800 $11.0m1.70% 1.70% AddedShares held: Q3 2025 0, Q4 2025 170.0k, Q1 2026 195.0k, Q2 2026 355.8k +160.8k +160,800 82.5%
15 ENLIVEN THERAPEUTICS INC COM ELVN ELVN 212,500 $10.8m1.67% 1.67% AddedShares held: Q3 2025 250.8k, Q4 2025 308.1k, Q1 2026 200.0k, Q2 2026 212.5k +12.5k +12,500 6.2%
16 DIANTHUS THERAPEUTICS INC COM DNTH DNTH 108,000 $10.5m1.63% 1.63% AddedShares held: Q3 2025 125.0k, Q4 2025 150.0k, Q1 2026 93.9k, Q2 2026 108.0k +14.1k +14,118 15.0%
17 ALLOGENE THERAPEUTICS INC COM ALLO ALLO 5,050,000 $10.5m1.63% 1.63% AddedShares held: Q3 2025 3.0m, Q4 2025 5.0m, Q1 2026 3.5m, Q2 2026 5.0m +1.6m +1,600,000 46.4%
18 EYEPOINT PHARMACEUTICALS INC COM NEW EYPT EYPT 720,000 $10.3m1.59% 1.59% ReducedShares held: Q3 2025 1.0m, Q4 2025 780.0k, Q1 2026 795.0k, Q2 2026 720.0k -75.0k -75,000 -9.4%
19 ARCUTIS BIOTHERAPEUTICS INC COM ARQT ARQT 370,000 $9.7m1.50% 1.50% ReducedShares held: Q3 2025 0, Q4 2025 210.0k, Q1 2026 400.6k, Q2 2026 370.0k -30.6k -30,645 -7.7%
20 C4 THERAPEUTICS INC COM STK CCCC CCCC 1,608,815 $7.5m1.16% 1.16% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 1.6m
21 INVENTIVA SA ADS IVA IVA 1,967,171 $7.4m1.15% 1.15% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 2.0m
22 KYMERA THERAPEUTICS INC COM KYMR KYMR 47,500 $5.4m0.84% 0.84% ReducedShares held: Q3 2025 92.6k, Q4 2025 139.0k, Q1 2026 100.0k, Q2 2026 47.5k -52.5k -52,500 -52.5%
23 FAETH THERAPEUTICS INC COM NEW FTH FTH 175,050 $4.4m0.68% 0.68% NewShares held: Q3 2025 0, Q4 2025 0, Q1 2026 0, Q2 2026 175.1k

Sold out since Q1 2026

SecurityTickerShares held beforeValue then
INSMED INC INSM INSM 157,500 $25.8m157.5k shares
LEGEND BIOTECH CORP LEGN LEGN 990,000 $17.9m990.0k shares
NEKTAR THERAPEUTICS NKTR NKTR 210,000 $15.1m210.0k shares
CELCUITY INC CELC CELC 95,000 $10.8m95.0k shares
MERCK & CO INC MRK MRK 80,000 $9.6m80.0k shares
PERSPECTIVE THERAPEUTICS INC CATX CATX 1,625,000 $6.8m1.6m shares
DEFINIUM THERAPEUTICS INC DFTX DFTX 331,000 $6.3m331.0k shares
HARROW INC HROW HROW 165,209 $5.8m165.2k shares
PROTARA THERAPEUTICS INC TARA TARA 1,030,846 $5.4m1.0m shares
CYTOMX THERAPEUTICS INC CTMX CTMX 1,085,790 $5.1m1.1m shares
ASSEMBLY BIOSCIENCES INC ASMB ASMB 136,315 $3.8m136.3k shares
SPYRE THERAPEUTICS INC SYRE SYRE 1,000 $50.4k1.0k shares